• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Left Ventricular Wall Stress-Mass-Heart Rate Product and Cardiovascular Events in Treated Hypertensive Patients: LIFE Study Clinical Trial
In the Losartan Intervention for End Point Reduction in Hypertension (LIFE) study, 4.8 years’ losartan- versus atenolol-based antihypertensive treatment reduced left ventricular hypertrophy and cardiovascular end points, including cardiovascular death and stroke. However, there was no difference in myocardial infarction (MI), possibly related to greater reduction in myocardial oxygen demand by atenolol-based treatment. Myocardial oxygen demand was assessed indirectly by the left ventricular massxwall stressxheart rate (triple product) in 905 LIFE participants. The triple product was included as time-varying covariate...
Source: Hypertension - October 7, 2015 Category: Cardiology Authors: Devereux, R. B., Bang, C. N., Roman, M. J., Palmieri, V., Boman, K., Gerdts, E., Nieminen, M. S., Papademetriou, V., Wachtell, K., Hille, D. A., Dahlof, B. Tags: Hypertrophy, Other etiology Clinical Trial Source Type: research

Abstract 241: Splenic T Regulatory Lymphocytes Are Reduced in Genetically Hypertensive Rats Associated with Central Sympathoexcitation Poster Session I
Conclusion: Our findings indicate that splenic Tregs are reduced in SHRSP at both prehypertensive and established hypertensive stages. These alterations may contribute to the development and maintenance of hypertension. Central sympathoinhibition increases the reduced splenic Tregs in SHRSP suggesting interaction between sympathetic hyperactivity and Tregs.
Source: Hypertension - October 30, 2013 Category: Cardiology Authors: Katsuki, M., Hirooka, Y., Kishi, T., Sunagawa, K. Tags: Poster Session I Source Type: research